Latest News
The artificial intelligence chipmaker got a double dose of good news.
Via The Motley Fool · May 13, 2025
Via The Motley Fool · May 13, 2025
Even without trouble from tariffs, Indie Semiconductor stock is probably a sell.
Via The Motley Fool · May 13, 2025
Risk management is one of the most crucial elements of successful financial planning, serving as the foundation for both protecting your assets and achieving your long-term financial goals.
Via Talk Markets · May 13, 2025
Amazon stock and Meta stock were both pushing higher after Trump slashed newly imposed tariffs on small e-commerce packages from China.
Via Investor's Business Daily · May 13, 2025
Dan Loeb's Third Point portfolio had mixed earnings results this week, with decreased stakes in Cinemark and Corpay, and an acquisition of AvidXchange.
Via Benzinga · May 13, 2025
NuScale Power shares surged 21% on Tuesday. The stock is up following the release of its Q1 earnings after Monday's close.
Via Benzinga · May 13, 2025
Under Armour beats Q4 sales estimates despite revenue drop, issues cautious Q1 guidance amid ongoing restructuring.
Via Benzinga · May 13, 2025
Via Benzinga · May 13, 2025
Via Benzinga · May 13, 2025
Via Benzinga · May 13, 2025
Meta Platforms shares have gained 10.6% since Monday's session open. The stock has been lifted by a broader rally in tech stocks following a tariff rollback agreement between the U.S. and China.
Via Benzinga · May 13, 2025
Via The Motley Fool · May 13, 2025
Bank of America disclosed expansion plans; the goal is to open over 150 new locations across 60 markets by the end of 2027.
Via Benzinga · May 13, 2025
Via Benzinga · May 13, 2025
After opening on a negative note, Indian benchmark indices extended their downward momentum throughout the session, ending in the red.
Via Talk Markets · May 13, 2025
The company reported positive free cash flow of $13.3 million for the first time since going public in February 2003.
Via Stocktwits · May 13, 2025
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Via Stocktwits · May 13, 2025